Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 148.00 GBp
Change Today -3.50 / -2.31%
Volume 16.5K
As of 11:30 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

summit therapeutics plc (SUMM) Snapshot

Open
151.50 GBp
Previous Close
151.50 GBp
Day High
151.50 GBp
Day Low
148.00 GBp
52 Week High
03/2/15 - 185.00 GBp
52 Week Low
12/3/14 - 107.00 GBp
Market Cap
90.7M
Average Volume 10 Days
72.0K
EPS TTM
-0.26 GBp
Shares Outstanding
61.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SUMMIT THERAPEUTICS PLC (SUMM)

Related News

No related news articles were found.

summit therapeutics plc (SUMM) Related Businessweek News

No Related Businessweek News Found

summit therapeutics plc (SUMM) Details

Summit Therapeutics plc operates as a biopharmaceutical company primarily in the United Kingdom and the Unites States. It focuses on the discovery, development, and commercialization of novel medicines to treat the Duchenne Muscular Dystrophy (DMD), a fatal muscle wasting disease; and infections caused by Clostridium difficile bacteria (CDI). The company develops SMT C1100, an utrophin modulator that is in Phase Ib clinical study for the treatment of DMD; and SMT 19969, a novel antibiotic, which is in Phase II proof of concept clinical trial for the treatment of CDI. It has strategic alliance with the University of Oxford to develop the future generation utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is headquartered in Abingdon, the United Kingdom.

25 Employees
Last Reported Date: 05/7/15
Founded in 2003

summit therapeutics plc (SUMM) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 330.0K GBP
Chief Financial Officer
Total Annual Compensation: 198.5K GBP
Compensation as of Fiscal Year 2015.

summit therapeutics plc (SUMM) Key Developments

Summit Therapeutics plc Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended July 31, 2015

Summit Therapeutics plc reported unaudited consolidated earnings results for the second quarter and six months ended July 31, 2015. For the quarter, the company reported other operating income were £0.4 million compared to £0.5 million for the three months ended July 31, 2014. Operating loss was £4.799 million against £3.578 million a year ago. Loss before income tax was £4.790 million against £3.556 million a year ago. Loss for the period attributable to owners of the parent was £4.033 million against £3.282 million a year ago. Basic and diluted loss per ordinary share from continuing operations was 7 pence against 8 pence a year ago. For the six months, the company reported other operating income were £0.8 million compared to £1.1 million for the six months ended July 31, 2014. Operating loss was £8.599 million against £6.397 million a year ago. Loss before income tax was £8.583 million against £6.372 million a year ago. Loss for the period attributable to owners of the parent was £7.399 million against £5.906 million a year ago. Basic and diluted loss per ordinary share from continuing operations was 13 pence against 15 pence a year ago. Net cash used in operating activities was £6.958 million against £5.299 million a year ago. Purchase of property, plant and equipment was £0.024 million against £0.016 million a year ago.

Summit Therapeutics plc to Report Q2, 2016 Results on Aug 27, 2015

Summit Therapeutics plc announced that they will report Q2, 2016 results at 12:00 PM, GMT Standard Time on Aug 27, 2015

Summit Therapeutics plc, Q2 2016 Earnings Call, Aug 27, 2015

Summit Therapeutics plc, Q2 2016 Earnings Call, Aug 27, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SUMM:LN 148.00 GBp -3.50

SUMM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SUMM.
View Industry Companies
 

Industry Analysis

SUMM

Industry Average

Valuation SUMM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUMMIT THERAPEUTICS PLC, please visit www.summitplc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.